US 11,787,860 B2
Anti-CD47 antibodies and uses thereof
Aaron Sato, Burlingame, CA (US); Ryan Stafford, Foster City, CA (US); and Junhao Yang, Palo Alto, CA (US)
Assigned to CELGENE CORPORATION, Summit, NJ (US)
Filed by CELGENE CORPORATION, Summit, NJ (US)
Filed on Oct. 29, 2020, as Appl. No. 16/949,459.
Application 16/949,459 is a division of application No. 15/541,003, granted, now 10,870,699, previously published as PCT/US2015/067642, filed on Dec. 28, 2015.
Claims priority of provisional application 62/098,291, filed on Dec. 30, 2014.
Prior Publication US 2021/0054070 A1, Feb. 25, 2021
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01); C12P 21/02 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 39/39541 (2013.01); A61K 45/06 (2013.01); C12P 21/02 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 21 Claims
 
1. A method of treating cancer, or alleviating a symptom of cancer, the method comprising administering a monoclonal anti-CD47 antibody which specifically binds to human CD47 to a subject in need thereof, wherein the anti-CD47 antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence:
(SEQ ID NO: 20)
X1QX2QLVQSGAEVKKX3GX4SVKVSCKASGFNIKDYYLHWVRQAPGQX5
 
LEWMGWIDPDQGDTEYAQKX6QX7RVTX8TX9DX10SX11STAYMELX12
 
SLRSX13DTAX14YYCNAAYGSSSYPMDYWGQGTTVTV,
wherein X1 is M or there is no amino acid at position X1, X2 is M or V, X3 is P, X4 is S or A, X5 is A or G, X6 is F or L, X7 is G, X8 is I or M, X9 is R or T, X10 is R or T, X11 is T, X12 is R, X13 is E or D, and X14 is V;
wherein the anti-CD47 antibody comprises a light chain variable region (VL) comprising CDR1, CDR2, and CDR3 comprising amino acid sequences KASQDIHRYLS (SEQ ID NO:17), RANRLVS (SEQ ID NO: 18), and LQYDEFPYT (SEQ ID NO:19), respectively.